TrialJournal of hematology & oncology2021

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

Farhad Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.